You're contacting media contact of this press release

Title: The Complete Weight Loss Transformation: Reign Beauty and Vitality Pioneers Integrated Aesthetic Protocol for GLP-1 Patients

United States, 26th Sep 2026 – Reign Beauty and Vitality announces comprehensive aesthetic protocol for patients pursuing medical weight loss with GLP-1 medications, addressing the rapidly emerging "Ozempic face" phenomenon: dramatic facial volume loss, skin laxity, and aged appearance occurring simultaneously with weight loss success.GLP-1 receptor agonists—including semaglutide (Ozempic, Wegovy), tirzepatide (Mounjaro, Zepbound), and similar medications—have transformed medical weight loss. Approximately 31 million Americans currently use GLP-1 medications for weight management. These medications are remarkably effective, producing 15-22% body weight loss over 68-72 weeks.However, rapid weight loss creates unintended aesthetic consequence: facial volume loss and skin laxity occurring faster than skin can adapt. The result is "Ozempic face"—gaunt, aged appearance despite successful weight loss. Patients achieve their weight loss goals yet look older and more tired than before treatment began."We're seeing unprecedented demand for aesthetic integration with GLP-1 weight loss," said Nika Asistio, NP, lead practitioner at Reign Beauty and Vitality. "Patients are thrilled about weight loss results. Then they see their face in photos and are devastated. Facial volume has disappeared. Skin is loose and sagging. They look 10-15 years older. This isn't vanity—it's the biological reality of rapid weight loss. The solution is comprehensive aesthetic integration managing facial changes simultaneously with weight loss."Why Facial Volume Loss Occurs During Rapid Weight LossThe face contains specialized fat compartments providing structure and volume. During rapid weight loss, facial fat is preferentially mobilized before body fat. Research demonstrates that facial fat compartments...

This press release is issued by King Newswire